Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone425-527-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$654.70 million
Profitability
Miscellaneous
Employees1,302
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Tuesday, July, 16th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.10. The biotechnology company earned $218.45 million during the quarter, compared to analysts' expectations of $189.76 million. Seattle Genetics had a negative return on equity of 17.16% and a negative net margin of 36.94%. The business's quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What guidance has Seattle Genetics issued on next quarter's earnings?
Seattle Genetics issued an update on its FY 2019 earnings guidance on Tuesday, July, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $805-855 million, compared to the consensus revenue estimate of $814.91 million.
What price target have analysts set for SGEN?
14 brokerages have issued 1-year price objectives for Seattle Genetics' shares. Their forecasts range from $70.00 to $101.00. On average, they anticipate Seattle Genetics' stock price to reach $85.2727 in the next year. This suggests a possible upside of 17.2% from the stock's current price. View Analyst Price Targets for Seattle Genetics.
What is the consensus analysts' recommendation for Seattle Genetics?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. According to Zacks Investment Research, "Seattle Genetics reported narrower-than-expected loss in Q1 while revenues beat estimates.Its sole marketed drug, Adcetris, is performing well since its launch. Adcetris’ recent label expansion in frontline stage III/IV Hodgkin lymphoma and in frontline CD30-expressing peripheral T-cell lymphomas (PTCL) bodes well for the company. The company’s collaboration with Takeda for the global development and commercialization of Adcetris also holds promise. However, its heavy dependence solely on Adcetris for growth is a concern. The recent label expansion of Merck’s Keytruda and Bristol-Myers’ Opdivo in the lymphoma indication will increase competition. Though the company has multiple candidates in its pipeline, maximum is in early developmental stages. Any regulatory setback for Adcetris could hurt its sales potential significantly." (5/29/2019)
- 2. JPMorgan Chase & Co. analysts commented, "Quarter as We maintain our Neutral rating on ZBH shares following 1Q19 results that came in-line with Street expectations (but missed our more bullish forecast) on the top-line with slightly higher expenses than we forecasted. While Hips (+1.7% xFx) and Dental (-0.2% xFx) were bright spots relative to expectations, Knees (+0.7% xFx) continues to remain challenged relative to market growth particularly within the Americas (-0.9% xFx). Importantly volume gains overall were +220bps Y/Y and only negative 30bps Q/Q from a seasonally strong 4Q18. While pricing pressures have not abated, we think the volume gains are notable for ZBH considering the overall pricing environment seen across all large cap orthopedics thus far this season." (4/28/2019)
- 3. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.1 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.6 platform + $2.6 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. April 26, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (4/26/2019)
Has Seattle Genetics been receiving favorable news coverage?
Press coverage about SGEN stock has been trending negative on Thursday, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Seattle Genetics earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Seattle Genetics.
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), Moderna (MRNA), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Allogene Therapeutics (ALLO), Ablynx (ABLYF) and Crispr Therapeutics (CRSP).
What other stocks do shareholders of Seattle Genetics own?
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 58)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)
- Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 62)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (8.76%), Vanguard Group Inc. (5.81%), Price T Rowe Associates Inc. MD (5.07%), BlackRock Inc. (5.05%), BlackRock Inc. (5.05%) and Baillie Gifford & Co. (4.13%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Jean I Liu, Jonathan G Drachman, Marc E Lippman, Roger D Dansey, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which institutional investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Canada Pension Plan Investment Board, Primecap Management Co. CA, Bank of America Corp DE and Morgan Stanley. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, David W Gryska, Jean I Liu, Roger D Dansey, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which institutional investors are buying Seattle Genetics stock?
SGEN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nuveen Asset Management LLC, Manning & Napier Group LLC, First Trust Advisors LP, Invesco Ltd., DekaBank Deutsche Girozentrale, Waddell & Reed Financial Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $72.78.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $11.77 billion and generates $654.70 million in revenue each year. The biotechnology company earns $-222,690,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Seattle Genetics employs 1,302 workers across the globe.View Additional Information About Seattle Genetics.
What is Seattle Genetics' official website?
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
